A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome

Registry ID

EUCTR2011-005535-68

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Farmacéutica, S.A.

Start date

2012-10-04

Last update

2026-08-16

Conditions

• Familial Chylomicronemia Syndrome (FCS)
• Familial Chylomicronemia Syndrome

Summary

The purpose of this study is to determine whether LCQ908 is effective and safe in lowering triglycerides in subjects with Familial Chylomicronemia Syndrome (FCS) (Hyperlipoproteinemia [HLP] type I). Data from this study will be used to support a registration submission of LCQ908 20 mg and 40 mg as treatment of chylomicronemia in subjects with FCS (HLP Type I).

Locations

• , , Germany
• , , Netherlands
• , , UK
• , , Spain

Related clinical trials

• A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
• CS-121 APOC3 Base Editing in FCS

View on source registry